(NP (NP (JJ Severe) (NN 5-fluorouracil) (NN toxicity)) (ADJP (JJ secondary) (PP (TO to) (NP (NN dihydropyrimidine) (NN dehydrogenase) (NN deficiency)))) (. .))
(NP (NP (DT A) (ADJP (RB potentially) (RBR more) (JJ common)) (JJ pharmacogenetic) (NN syndrome)) (. .))
(S (NP-SBJ (DT This) (NN study)) (VP (VBZ describes) (NP (NP-COOD (NP (NP (DT the) (NN inheritance)) (PP (IN of) (NP (NP (DT a) (NN defect)) (PP (IN in) (NP (NN pyrimidine) (NN catabolism)))))) (CC and) (NP (NP (PRP$ its) (NN association)) (PP (IN with) (NP (JJ drug-induced) (NN toxicity))))) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NN 5-fluorouracil) (PRN (-LRB- -LRB-) (NP (NN FUra)) (-RRB- -RRB-))) (PP (IN as) (NP (NP (JJ adjuvant) (NN chemotherapy)) (PP (IN for) (NP (NN breast) (NN carcinoma)))))))))) (. .))
(S (NP-SBJ (DT The) (NN study) (NN population)) (VP (VBD included) (NP-COOD (NP (NP (NP (DT the) (VBN affected) (NN patient)) (PRN (-LRB- -LRB-) (NP (NN proband)) (-RRB- -RRB-))) (, ,) (NP (NP (CD nine)) (PP (IN of) (NP (PRP$ her) (NN blood) (NNS relatives)))) (, ,)) (CC and) (NP (CD seven) (JJ healthy) (NNS volunteers)))) (. .))
(S (NP-SBJ-30 (NP (DT The) (NN activity)) (PP (IN of) (NP (NP (NP (NP (NN dihydropyrimidine) (NN dehydrogenase)) (PRN (-LRB- -LRB-) (NP (NN DPD)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (JJ initial) (NN enzyme)) (PP (IN of) (NP (NP-COOD (NP (NN pyrimidine)) (-LRB- -LRB-) (CC and) (NP (NN FUra)) (-RRB- -RRB-)) (NN catabolism)))) (, ,)) (PP (IN in) (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells)))))) (VP (VBD was) (VP (VBN measured) (NP (-NONE- *-30)) (PP (IN in) (NP (DT each) (NN subject))) (PP (IN by) (NP (NP (DT a) (JJ specific) (JJ radiometric) (NN assay)) (VP (VBG using) (NP (NN FUra)) (PP (IN as) (NP (DT the) (NN substrate)))))))) (. .))
(S (NP-SBJ (DT The) (NN proband)) (VP (VBD had) (NP (DT no) (JJ detectable) (NN DPD) (NN activity))) (. .))
(S (SBAR-TMP (WHADVP-101 (WRB When)) (S (NP-SBJ-31 (NP (NN enzyme) (NNS levels)) (PP (IN in) (NP (DT the) (NP-COOD (NP (NN proband)) (CC and) (NP (NNS relatives)))))) (VP (VBD were) (VP (VBN compared) (NP (-NONE- *-31)) (PP (IN with) (NP (NP (DT that)) (PP (IN in) (NP (NNS controls))))) (ADVP (-NONE- *T*-101)))))) (, ,) (NP-SBJ-32 (NP (DT an) (JJ autosomal) (JJ recessive) (NN pattern)) (PP (IN of) (NP (NN inheritance)))) (VP (VBD was) (VP (VBN demonstrated) (NP (-NONE- *-32)))) (. .))
(S (NP-SBJ (DT This)) (VP (VBZ is) (NP-PRD-COOD (NP (NP (DT the) (JJ third) (NN patient)) (PP (IN with) (NP (NP (JJ severe) (NN FUra) (NN toxicity)) (ADJP (JJ secondary) (PP (TO to) (NP (NP (DT an) (NN alteration)) (PP (IN in) (NP (NN pyrimidine) (NN catabolism))))))))) (CC and) (NP (NP (DT the) (NN second)) (PP (IN from) (NP (PRP$ our) (NN clinic) (NN population))))) (S (NP-SBJ (-NONE- *)) (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN frequency)) (PP (IN of) (NP (DT this) (JJ genetic) (NN defect)))) (VP (MD may) (VP (VB be) (ADJP-PRD (ADJP (JJR greater)) (SBAR (IN than) (S (NP-SBJ-33 (-NONE- *)) (ADVP-TMP (RB previously)) (VP (VBN thought) (NP (-NONE- *-33))))))))))))) (. .))
(S (S-SBJ (NP-SBJ (-NONE- *)) (VP (VBG Monitoring) (NP (NN DPD) (NN activity)))) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ important)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG experiencing) (NP (NP (JJ severe) (NN toxicity)) (ADJP (JJ secondary) (PP (TO to) (NP (NN FUra) (NN chemotherapy)))))))))))) (. .))
